Interní Med. 2017; 19(4): 217-219 [Klin Farmakol Farm. 2017;31(1):37-39]

Paget Schroetter syndrome – clinical case of effort thrombosis

MUDr. Petr Grenar, MUDr. Dan Rakušan, MUDr. Tomáš Adámek, Ph.D., doc. MUDr. Pavel Kohout, Ph.D.
Interní oddělení, Thomayerova nemocnice, Praha

Paget Schroetter syndrome (idiopatic thrombosis of upper extremity, exertional thrombosis) is generally rare clinical conditionwith progressively worsening symptoms, which affects mainly young patients. In cases with delayed diagnostic processand inappropriate treatment, it tends to have long term impact on patients health status. This article is mainly concerned withrecomended diagnostic and treatment approaches to Paget Schroertter syndrome. There is a case report included in order toprove a manifestation of the syndrome in clinical practice.

Keywords: Paget-Schroetter syndrome, idiopatic thrombosis of upper extremity, exertional thrombosis, thoracic outlet syndrome

Received: February 25, 2019; Accepted: March 6, 2019; Prepublished online: March 6, 2019; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grenar P, Rakušan D, Adámek T, Kohout P. Paget Schroetter syndrome – clinical case of effort thrombosis. Interní Med. 2017;19(4):217-219.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Karetová D, Bultas J. Cilostazol. Remedia 2014; 441-449.
    2. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACC/AHA focused update of the Guidelines for the management of patients with peripheral artery disease (updating the 2005 guidelines). Circulation 2011; 124: 2020-2045. Go to original source... Go to PubMed...
    3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33: S1-S70. Go to original source... Go to PubMed...
    4. Bedenis R, Stewart M, Cleanthis S, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014 Oct 31; (10): CD003748. doi: 10.1002/14651858.CD003748.pub4. Go to original source... Go to PubMed...
    5. Gotoh F, Hideo T, Shunsaku H, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157. Go to original source... Go to PubMed...
    6. Uschiyama S. Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients. Rinsho Shinkeigaku 2010; 50: 832-834. Go to original source... Go to PubMed...
    7. Prat C. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87: 28D-33D. Go to original source... Go to PubMed...
    8. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.